Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasiti... (eart failure altered heart rate and card...)

Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases

Date:8/27/2007

eart failure, altered heart rate and cardiac arrest, and intestinal complications include an enlarged esophagus or colon. The average lifetime risk of Chagas-infected individuals developing these complications is about 30%. Anti-parasitic medications are usually only effective when given during the acute stage. They can be very toxic, and resistance has already been reported. In the chronic stage of Chagas disease, treatment is limited to managing the clinical manifestations. The scale of the problem is highlighted by the fact that chronic heart disease caused by Chagas is now a major reason for heart transplantation surgery in South America.

Notice Regarding Forward-Looking Statements: This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, the expectation and/or claim, as applicable, that: (i) Pacific Pharma's technologies may have potential applications against major tropical parasitic diseases; (ii) Pacific Pharma's technologies may have substantial commercial potential and such technologies fit well with the Company's core competencies in computational-based approaches to biomarker identification; (iii) the Company intends to begin screening compounds against malaria and to test compounds from related classes as potential therapies for tuberculosis; (iv) the Company intends to work with a variety of public and private organizations to ensure timely and cost-effective clinical development of drug candidates generated by its technologies; (v) the Company expects to pursue other therapeutic applications of the technology going forward
'/>"/>

SOURCE Upstream Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

Post Your Comments:

Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasiti...(eart failure altered heart rate and card...),Health